CA-JUNIPER-NETWORKS
23.5.2023 09:01:35 CEST | Business Wire | Press release
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Korian Benelux, part of a major European healthcare and long-term elderly care organization, selected Juniper’s AI-driven enterprise solutions, including wireless and wired access, to optimize network performance and reliability and deliver personalized care for its residents.
More than 11 thousand Korian employees provide care for approximately 15 thousand residents in 173 locations in The Netherlands and Belgium. Korian was drawn to the Mist AI engine with cloud-hosted operations to give its IT team greater insights into user experiences and better troubleshooting for connected medical Wi-Fi devices and phones. The real-time insights, provided by Juniper Mist Wired Assurance, Juniper Mist Wireless Assurance and the Marvis™ Virtual Network Assistant, have simplified troubleshooting at the customer, device and site level for better service quality. By leveraging Mist AI, the Juniper solution delivers customizable service levels and actionable recommendations to proactively fix issues, often before users are impacted. As a result, users experience a more reliable network infrastructure with less downtime, due to the Juniper Mist AI predictive approach. Centralized configuration and zero-touch provisioning simplify onboarding new Juniper access points and switches as facilities are updated. When Korian does a renovation, the network can be installed in one day, compared to two days with their previous wireless solution.
Staying connected to families and friends is important to the well-being of Korian’s residents and short-term recovery patients, whether they like to call, video chat or email. Residents can use tablets in their rooms to watch movies, listen to their favorite music and call the nursing staff if they need help. Voice communications are loud and clear. Families and friends have guest Wi-Fi when they come to visit.
Korian staff have fast, responsive access to their long-term care, clinical and administrative applications, so they can stay productive and focused on patient care. Smart medical devices have the more reliable connectivity necessary for Korian to provide optimal care.
The organization adopted Juniper Wireless Access Points and Wireless Assurance driven by Mist AI to deliver better resident engagement, coupled with industry-leading Wi-Fi that is both more predictable and more reliable. In addition, Juniper Networks EX Series Switches and Juniper Mist Wired Assurance provide high-performance, more secure access to the access points and other wired devices. Juniper was named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.
Korian Benelux Group worked with Nomios, a Juniper Elite Plus partner, to create the optimal network architecture, focusing on network design, validation and testing to ensure that the Juniper solutions met strategic and technical goals.
Supporting Quotes:
“With our new network, our nursing staff have resilient access to medical and administrative applications. Computers on wheels and other smart medical equipment are always connected. Residents and their families can now easily connect to the Wi-Fi. IT has clear visibility into service level expectations and what we’re actually delivering. With Juniper Mist, we can see any Wi-Fi problems ourselves immediately, instead of waiting for nursing staff to tell us. Ultimately, we spend less time troubleshooting, and that frees up our time for more strategic priorities.”
- Christoph Van Doren, ICT Director, Korian Benelux
“Healthcare organizations are constantly looking to leverage innovative technology to deliver a high-touch experience for residents, guests and staff. The network plays a vital role at Korian by keeping its technology infrastructure healthy. It allows them to simply scale and support new applications and technologies that can assist in driving better resident outcomes and experiences.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Korian: Success Story
- 2022 Gartner Magic Quadrant for Enterprise Wired and Wireless LAN Infrastructure: View Report
- Blog: When it Comes to Wired & Wireless Access, Juniper Mist is in the Driver’s Seat
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
